Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Cash from Operations (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Cash from Operations for 4 consecutive years, with 18653000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 28.81% to 18653000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 93405000.0 through Dec 2025, up 27.26% year-over-year, with the annual reading at 93405000.0 for FY2025, 27.26% up from the prior year.
  • Cash from Operations hit 18653000.0 in Q4 2025 for Axsome Therapeutics, down from 1046000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 1046000.0 in Q3 2025 to a low of 55349000.0 in Q2 2023.
  • Historically, Cash from Operations has averaged 30212875.0 across 4 years, with a median of 30236000.0 in 2023.
  • Biggest five-year swings in Cash from Operations: plummeted 818.52% in 2024 and later surged 105.61% in 2025.
  • Year by year, Cash from Operations stood at 27563000.0 in 2022, then decreased by 10.15% to 30362000.0 in 2023, then increased by 13.7% to 26202000.0 in 2024, then rose by 28.81% to 18653000.0 in 2025.
  • Business Quant data shows Cash from Operations for AXSM at 18653000.0 in Q4 2025, 1046000.0 in Q3 2025, and 32423000.0 in Q2 2025.